Universe Pharmaceuticals Inc
1 hedge funds and large institutions have $12K invested in Universe Pharmaceuticals Inc in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
107% more capital invested
Capital invested by funds: $5.81K → $12K (+$6.19K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$808 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Acadian Asset Management
Boston,
Massachusetts
| $12K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| – | -$808 | -1 | Closed |
|
UPC Hedge Fund Activity: Q4 2023 in Review
1 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Universe Pharmaceuticals Inc (UPC) for Q4 2023, worth a combined $12K — up 107% from $5.81K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of UPC and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $808 sold.
- 1 institutional investor held Universe Pharmaceuticals Inc (UPC) as of Q4 2023, down from 2 in Q3 2023.
- Funds reported $12K of Universe Pharmaceuticals Inc stock for Q4 2023, up 107% quarter-over-quarter.
- 0 funds opened new Universe Pharmaceuticals Inc positions in Q4 2023 and 1 closed out, a net change of -1 holder.
- The largest Universe Pharmaceuticals Inc seller in Q4 2023 was UBS Group, an estimated $808 sold.
Based on aggregated 13F filings for Q4 2023.